- Dosing is underway in a Japan-based Phase 2 clinical trial evaluating Ablynx's (OTCPK:ABLYF) ALX-0171 inhaled Nanobody for the treatment of respiratory syncytial virus (RSV) infections.
- More news on: Ablynx NV, Healthcare stocks news, Read more ...
home / stock / ablyf / ablyf news
Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.